Omeros Corporation

Omeros Corporation is a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutics for a range of serious and unmet medical needs. The company's pipeline focuses on small-molecule and protein-based drugs targeting immunologic diseases, with a particular emphasis on rare or "orphan" indications. Omeros' lead product candidate, narsoplimab, is a MASP-2 inhibitor being investigated for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA), a life-threatening complication of stem cell transplantation. Narsoplimab is also being explored for its potential in treating COVID-19 and acute respiratory distress syndrome. Beyond narsoplimab, Omeros is advancing other promising candidates, including OMS1029, a MASP-2 inhibitor for lectin pathway disorders, and zaltenibart, which is in late-stage clinical trials for paroxysmal nocturnal hemoglobinuria and being evaluated for complement 3 glomerulopathy and other alternative pathway disorders. The company's research also extends to novel treatments for addictions, compulsive disorders, movement disorders, and various cancers, with several programs in preclinical development. Omeros leverages its deep understanding of the complement system and immunologic pathways to create innovative therapies.